Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

HYDROCHLOROTHIAZIDE

All products: general benefit

Mint-Hydrochlorothiazide · DIN 02426196 · 25mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mint-Hydrochlorothiazide · DIN 02426196 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2015-03-31 Daily cost (source): $0.0157 Health Canada: Marketed since 2018-08-30 · brand MINT-HYDROCHLOROTHIAZIDE · ATC C03AA03 HYDROCHLOROTHIAZIDE · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 25 MG · company Mint pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mint-Hydrochlorothiazide: Formulary list price $0.0157/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0157 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91079 · Verify on the e-Formulary ↗ (DIN 02426196)

Source record
DIN 02426196: Mint-Hydrochlorothiazide Raw flags: chronicUseMed=Y, sec3=Y Item: 402800012; group id 561; item number 1502; lccId None; manufacturer id MIN Source form: Tab; strength: 25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.0157; ministry $0.0157 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02426196 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91079
Interchangeable products
Apo-Hydro 25 · DIN 00326844 · $0.0157 HydroDIURIL · DIN 00016500 · not recorded PMS-Hydrochlorothiazide · DIN 02247386 · $0.0157 Teva-Hydrochlorothiazide · DIN 00021474 · $0.0157
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02426196
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (40:28 Diuretics) and how they are covered

Matched class: 40:28 Diuretics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMILORIDE HCL, METOLAZONE, SPIRONOLACTONE Some products covered without a code (check the product listing): AMILORIDE HCL & HYDROCHLOROTHIAZIDE, CHLORTHALIDONE, FUROSEMIDE, HYDROCHLOROTHIAZIDE & SPIRONOLACTONE, HYDROCHLOROTHIAZIDE & TRIAMTERENE, INDAPAMIDE 40:28 Diuretics

AMILORIDE HCL

· 1 products · General benefit · strengths: 5mg · Tab

AMILORIDE HCL & HYDROCHLOROTHIAZIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 5mg & 50mg · Tab

CHLORTHALIDONE

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 50mg · Tab

FUROSEMIDE

· 14 products · Limited Use, codes 481, 657 (2), General benefit (9), Listed, not a benefit (2), Limited Use, codes 33 (1) · strengths: 10mg/mL, 20mg, 40mg, 500mg · Inj Sol (Preservative Free), O/L, Tab

HYDROCHLOROTHIAZIDE & SPIRONOLACTONE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 25mg & 25mg, 50mg & 50mg · Tab

HYDROCHLOROTHIAZIDE & TRIAMTERENE

· 3 products · General benefit (2), Listed, not a benefit (1) · strengths: 25mg & 50mg · Tab

INDAPAMIDE

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 1.25mg, 2.5mg · Tab

METOLAZONE

· 1 products · General benefit · strengths: 2.5mg · Tab

SPIRONOLACTONE

· 8 products · General benefit · strengths: 25mg, 100mg · Tab

MIDODRINE HCL

· 10 products · Listed, not a benefit (2), Limited Use, codes 01 (8) · strengths: 2.5mg, 5mg · Tab

TOLVAPTAN

· 10 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 15mg & 15mg, 30mg & 15mg, 45mg & 15mg, 60mg & 30mg, 90mg & 30mg · 14-Tabs Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 40:28
Full class listing Related classes: 40:12 Replacement Agents, 40:18 Potassium-Removing Resins, 40:40 Uricosuric Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE TEVA-HYDROCHLOROTHIAZIDE (Hydrochlorothiazide) is indicated for the treatment of: • Edema • Hypertension • Toxemia of Pregnancy Edema TEVA-HYDROCHLOROTHIAZIDE (hydrochlorothiazide) is indicated in edema associated with congestive heart failure, hepatic cirrhosis, corticosteroid and estrogen therapy, premenstrual tension with edema and in edema of renal origin (i.e. nephrotic syndrome, acute glomerulonephritis and chronic renal disease). In obese patients in whom fluid retention is a complicating factor, it may help to initiate a loss of fluid and, thus of weight. Hypertension TEVA-HYDROCHLOROTHIAZIDE may be used alone or as an adjunct to other antihypertensive drugs. Since it enhances the action of these agents, their dosage must be reduced to avoid an excessive drop in pressure and other unwanted side effects. Toxemia of Pregnancy TEVA-HYDROCHLOROTHIAZIDE may be effective in the treatment of toxemia of pregnancy (including eclampsia). TEVA-HYDROCHLOROTHIAZIDE Product Monograph Page 3 of 23 Geriatrics (> 65 years of age): No data is available. Pediatrics (0 to 12 years of age): See WA… https://pdf.hres.ca/dpd_pm/00074131.PDF PM date: December 29, 2023 Source product: TEVA-HYDROCHLOROTHIAZIDE; DIN 00021474; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.